Update shared on 10 Nov 2025
Fair value Increased 2.45%Analysts have raised their price target for Privia Health Group to approximately $30.89 from $30.15 per share, citing improved EBITDA guidance as a result of continued strong performance in shared savings programs.
Analyst Commentary
Recent analyst opinions reflect both confidence and caution regarding Privia Health Group's prospects. Updated price targets and earnings outlooks have contributed to ongoing discussion around the company’s valuation and growth trajectory.
Bullish Takeaways
- Improved EBITDA guidance, with 2025 projections raised to $113 million to $116 million. This supports expectations for sustained profitability and operational efficiency.
- Continued success in Medicare Shared Savings Program initiatives demonstrates effective execution in core healthcare partnerships. This fuels confidence in ongoing shared savings generation.
- Increased price targets indicate positive sentiment toward Privia Health’s growth strategy and the durability of its revenue streams.
- Bullish analysts see the company as well positioned to maintain consistent performance and deliver shareholder value over the coming year.
Bearish Takeaways
- Some analysts remain cautious regarding the challenge of sustaining elevated EBITDA margins over multiple years, especially amid ongoing shifts in healthcare reimbursement models.
- Valuation concerns arise as the company’s share price approaches updated targets, prompting questions about upside potential in the near term.
- Dependence on the success of shared savings programs introduces execution risk if regulatory or market conditions change.
What's in the News
- Privia Health Group has raised its 2025 full-year earnings guidance and now expects GAAP revenue between $2,050 million and $2,100 million, up from a previous range of $1,800 million to $1,900 million (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from $30.15 to approximately $30.89 per share.
- The discount rate increased modestly from 6.78% to 6.96%, reflecting a slightly higher required return.
- Revenue growth expectations improved from 11.82% to 11.99%.
- Net profit margin has grown from 2.86% to 3.48%, indicating a more favorable profitability outlook.
- Future P/E has fallen significantly from 63.35x to 50.02x, suggesting a more attractive valuation based on projected earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.